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Abstract  Gliosarcoma (GS) is a rare form of 
glioblastoma which express simultaneous gliomatous and 
sarcomatous transformation. Here, we reported a spinal cord 
gliosarcoma metastatic to spinal cord in a 3 years old boy, 
and discussed literature.  




GS is a rarely seen tumor at childhood. There are two 
incidence peaks in infantile period and at 10 years of age 1,2. 
Contrary to other brain tumors of childhood, it is localized at 
frontal and temporal lobes in supratentorial area in more than 
95% of the cases 3. On microscopy, biphasic pattern 
including glial and mesenchymal components is 
pathognomonic for gliosarcoma 4.   
Clinical behavior and survival are similar to glioblastoma. 
Prognosis is rather poor despite treatment modalities 
including surgical resection, radiotherapy, chemotherapy 
and combination therapies 5,8. GS has a high recurrence rate 
as it is a very aggressive tumor. Median survival ranges 
between 9 and 12 months 1, 4.  
Extracranial metastasis is extremely rare in gliosarcoma. 
In the literature, there are a few pediatric GS cases with 
extra-cranial metastasis 4. To best of our knowledge, there is 
no publication in the literature about spinal cord metastasis 
of gliosarcoma at thoracic level. Spinal cord metastasis 
occurs through CSF and it is fatal in almost all cases 5.  
Here, we presented a pediatric gliosarcoma case with 
spinal cord metastasis, and discussed relevant publications 
and treatment modalities.  
2. A Case Report 
An otherwise healthy, a 3 years old boy, presented with 
focal seizure over 3-4 minutes at right arm. There was no 
fever, vomiting or altered consciousness. On the magnetic 
resonance imaging (MRI), there was cortical thickening and 
increased cortical and sub-cortical signal intensity on 
T2-weighted images which involved left amygdale, left 
anterior temporal lob cortex and sub-cortical area and 
extended up to posterior occipital region (Figure 1). After 
gadolinium contrast administration, cortical nodular contrast 
enhancement at left occipital are, slightly increased choline, 
markedly decreased NAA and lactate peak on magnetic 
resonance spectroscopy were detected. MELAS syndrome, 
Rasmussen encephalitis and SSPE were considered in 
differential diagnosis, but these entities were eliminated as 
focal nodular contrast enhancement is atypical for these 
entities; and there was lack of hemorrhage and involvement 
at contralateral hemisphere. The patient was considered as 
low-grade glial tumor with recommendation of re-evaluation 
after 3-months follow-up. However, the patient presented 
with marked worsening in symptoms one month later. On the 
MRI, there were mass lesions including a lesion at parietal 
and occipital region extending from superior margin of 
tentorium to inferior margin of ventricle at the left 
(2.7x2.8x3.1 cm in size), another lesion at medial vicinity 
(1.6x1.1x.18 cm in size); in addition, multiple lesions with 
hemorrhage extending to posterior margin of corpus 
callosum (3.2x1.0x3.4 cm in size) and at adjacent area 
(3.5x1.7x2.6 cm in size). It was found that there was marked 
increase in size and number of lesions with contrast 
enhancement (Figure 2). Stereotactic biopsy was performed 
at temporal region. Pathological diagnosis was reported as 
gliosarcoma (grade 4). The patient was discussed at 
multidisciplinary meeting and it was planned to deliver 
chemotherapy with vincristine, cyclophosphamide, mesna 
alternating with temozolomide, carboplatin and etoposide. 
The patient received a session of methotrexate with a dose of 
5 g/m2; however, a control MRI was performed due to rapid 
deterioration in neurological symptoms. As there was an 
increase in number and size of mass lesions, broad local 
radiotherapy to cranium was initiated immediately. Spinal 
MRI was performed to the patient who displayed difficulty 
in walking on physical examination. However, spinal MRI 
could be performed 12 days after therapy nodular and linear 
contrast enhancement (5 mm in size) was observed at 
thoracic vertebrae 10-12 level, which was interpreted as 
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spinal seeding (Figure 3). Cranial radiotherapy was 
withdrawn at the dose of 16 Gy and craniospinal 
radiotherapy was initiated. Simultaneously, vincristine with 
a dose of 1 mg/m2 (weekly) was given to the patient. 
Radiotherapy was delivered with a total dose of 40 Gy (1.66 
Gy fractions per day) in the spinal canal and with a total dose 
of 40 Gy (1.81 Gy fractions per day) in the cranium. Total 
dose was completed to 56 Gy for gross mass lesions in the 
brain and 40 Gy for the spinal metastatic field. No 
hematological toxicity requiring withdrawal of radiotherapy 
was observed. Adjuvant chemotherapy was maintained by 
nimotuzumab and vinblastine. General health status was 
markedly deteriorated on the month 3 after radiotherapy. It 
was found that there was paralysis on 5th, 6th and 7th cranial 
nerves on physical examination. On MRI, diffuse metastatic 
foci and mass lesions extending from corpus cavernosum to 
brainstem were observed. Palliative radiotherapy was 
initiated directing mass lesions. Radiotherapy was delivered 
with a total dose of 9.6 Gy (1.60 Gy fractions per day). After 
palliative radiotherapy, recovery was detected in the 
paralysis of 5th cranial nerve. Chemotherapy was 
contraindicated due to poor general health status. The patient 
died 8 months after histopathological diagnosis because of 
progressive disease. 
 
Figure 1.  Axial T2-weighted cranial MRI scan shows cortical thickening with increased cortical and sub-cortical signal intensity on the left amygdale and 
anterior temporal lobe.  
 Cancer and Oncology Research 3(4): 49-52, 2015 51 
 
 
Figure 2.  Axial T1-weighted cranial MRI scan shows enhancing mass lesions on the left parietal and occipital region.  
 
Figure 3.  Sagittal T1-weighted post-contrast MRI of the thoracic spine demonstrates intramedullary metastatic lesion located at the level of thoracic level 
vertebrea 10-12 (arrows). 
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3. Discussion 
Gliosarcoma is the rarest primary malignant tumor of 
central nervous system in both children and adults. It 
comprises 2% of pediatric glial tumors. Symptoms vary 
according to localization and extent of tumor. Most common 
symptoms are epileptic seizures and dysphasia as majority of 
gliosarcoma is usually located in the cerebral hemispheres 
1,2,5,7. In the present case, mass localized at parietal and 
occipital region caused focal epileptic seizure.  
To date, 20 GS cases with extracranial metastasis via 
hematogenous route have been reported in the literature. 
Majority of these cases were adult patients with cervical cord, 
lung, liver and lymph node metastasis 4. In the literature, 
spinal cord metastasis is extremely rare in GS 2, 4 . 
In a study, a patient with glioblastoma multiforme (GBM), 
Pezeshkpour et al. reviewed 18,000 cases with primary 
central nervous system tumor and reported 18 cases with 
symptomatic metastasis 6. This indicated that metastasis 
occurs at late period after diagnosis of primary tumor. In a 
study by Grabb et al., 11 cases with metastasis were reported 
among 33 pediatric cases with malignant glioma. Of these 
cases, 4 were metastasis of GBM 2 . Packer et al. found 
metastasis rate as 18% among children with malignant 
glioma 6. This can be attributed to improved mean survival 
due to advances in diagnostic and therapeutic methods.  
Recommended treatment is radical excision of mass lesion 
without interrupting surrounding brain tissue in GS. After 
surgery, multimodal therapy is employed, including 
chemotherapy and radiotherapy. In the studies, median 
survival is found as 6 months in cases underwent surgery 
alone, while it is found to be prolonged up to 2 years in those 
received radiotherapy and chemotherapy in addition to 
surgical excision. Prognosis is rather poor in metastatic 
gliosarcoma and it is fatal in almost all cases 2,5,7. In our case, 
tumor was developed in multiple foci. The disease rapidly 
progressed and spinal involvement was detected after 
initiating therapy. No success was achieved in terms of 
disease progression despite all treatments. Multifocal disease 
onset made surgery impossible. In the cranium, relapse 
occurring within radiotherapy field suggested that 
radiotherapy dose of 40 Gy is insufficient. As spinal cord 
metastasis was detected during therapy, craniospinal 
radiotherapy was initiated instead of cranial radiotherapy. 
Additional radiotherapy doses were delivered to primary 
lesion and area with seeding. Systemic chemotherapy was 
maintained after radiotherapy. However, we could be able to 
achieve a median survival of 8 months by 
chemoradiotherapy and adjuvant chemotherapy without 
surgery.  
Gliosarcoma is an extremely rare tumor at childhood, 
which is localized at cerebral hemisphere and displays 
high-grade and biphasic pattern. Spinal cord metastasis of 
primary gliosarcoma is a rarely seen complication of 
gliosarcoma. If a simultaneous spinal cord metastasis is 
detected in a patient during treatment of primary intracranial 
gliosarcoma, treatment should include craniospinal 
radiotherapy. Adjuvant chemotherapy should be given after 
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